Omacetaxine mepesuccinate
CGX-635-CML-203
Phase 2 small_molecule completed
Quick answer
Omacetaxine mepesuccinate for Chronic Myeloid Leukemia is a Phase 2 program (small_molecule) at Teva Pharma GmbH with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Chronic Myeloid Leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed